Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has launched three new models in its Dako Omnis instrument family to address diverse pathology laboratory needs. The new lineup includes the Dako Omnis 110 for low-medium volume labs (110 IHC slides/day), Dako Omnis 165 for medium-high volume labs (165 IHC slides/day), and Dako Omnis 165 Duo for simultaneous IHC and ISH processing.
The new instruments feature continuous case-based processing, shared reagents, and an integrated direct connection for de-ionized water and non-hazardous waste to improve workflow efficiency. The products will be initially available in the U.S., Europe, and Australia, with debuts planned at the European Congress of Pathology and National Society for Histotechnology events.
Crawford & Company (NYSE: CRD-A and CRD-B) announced an increase in its quarterly dividend. The Board of Directors approved a quarterly dividend of $0.075 per share for both Class A and Class B Common Stock, representing a $0.005 increase from the previous quarter.
The dividend will be paid on August 29, 2025, to shareholders of record as of August 15, 2025.
Agilent Technologies (NYSE: A) has announced it will release its third quarter fiscal 2025 financial results on Wednesday, August 27, 2025, after market close. The company will host a conference call at 1:30 p.m. PDT the same day to discuss the results. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website. A replay of the call will remain available on the website for 90 days.
Agilent Technologies (NYSE: A) announced that Senior Vice President and CFO Bob McMahon will step down effective July 31, as he relocates to the East Coast for family reasons. Rodney Gonsalves, the company's current corporate controller and principal accounting officer, will serve as interim CFO while a global search for McMahon's successor is conducted.
The company also confirmed that its Q3 FY2025 financial results, to be released on August 27, are expected to be within the previously provided guidance range. Agilent maintains confidence in its long-term plans.
Agilent Technologies (NYSE: A) has appointed August Specht, Ph.D. as its new Chief Technology Officer, effective June 9, 2025. Specht joins Agilent from Thermo Fisher Scientific, where he served as vice president of Global R&D for the Chromatography and Mass Spectrometry Division. With over 25 years of experience in analytical instruments, software, and consumables development, Specht brings extensive expertise in R&D, product management, strategy, and business development from his roles at Thermo Fisher and Varian Instruments.
Specht holds a B.S. in Chemistry from Queen's University, a Ph.D. in Analytical Chemistry from the University of British Columbia, and an MBA from UC Berkeley. Agilent, a global leader in analytical and clinical laboratory technologies, reported revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide.